NCT05002270CompletedPhase 1/2
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 26 Jul 2021
- Start date
- 3 Sept 2021
- Primary completion date
- 12 Feb 2025
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Diseases
- Lung cancer
- NCT number
- NCT05002270
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 29
- From 3 Sept 2021 to the primary completion date, 12 Feb 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
- Active infection requiring systemic treatment within 7 days
- Active HBV or HCV
- Any severe and/or uncontrolled medical conditions
Lab values
- LVEF ≤50% assessed by ECHO or QTcF
- QT interval \>470 msec
Other
- Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities
Who the study is looking for
- Participants must be able to provide an archived tumor sample
- Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
- Must have received at least 1 prior standard therapy
- Must have at least 1 measurable lesion per RECIST v1.1
- Must have adequate organ function
- Must be able to swallow and retain orally administered medication
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinc Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| Mayo Clinc Coordinator of this site? Confirm its status | Phoenix | United States | Unknown status |
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
| Mayo Clinc Coordinator of this site? Confirm its status | Scottsdale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.